Pharmaceutical Commerce - January/February 2015

Roughly 40% are for rare diseases; PD-1 oncolytics capture industry attention

Mapi Group casts itself as a leading 'health research and commercialization' player

'Stay tuned' for interactions directly with pharma companies, says CEO Jeff Tangney

So long WAG, hello to WBA as pharma manufacturers look at a consolidating buyer landscape

Pharmacists' ranking, continuing a two-year decline, is now neck-and-neck with doctors

Express Scripts touts a 'fundamental change' in drug pricing; others would call it negotiating a discount

Acquisition builds on Dohmen's rare-disease business

Poltraf acquisition adds to a network of 14 facilities serving Eastern and Western Europe

Will formularies become a consumer's concern for healthcare provision?

The broad changes taking place in the pharma supply chain this year are a relevant focus for the annual conference and exhibition

FDA enforcement delay to May 1 isn't slowing down project work

Company hires Kevin O'Donnell, cold chain expert, to build out its Biologistex shipping service

Cloud computing opens a new array of benefits--and challenges--to data-sharing

Identity Management

Persistent drug shortages are mostly attributable to manufacturing quality problems, but the economics of low-margin generic manufacturing challenge the industry

When state and federal governments are involved, prices and reimbursements have both regulatory and financial consequences

Outsourced field sales is becoming only part of what CSOs are offering their pharma clients

Publicis Touchpoint Solutions does a deal with Cegedim Relationship Management

Internal compliance reviews are not enough; life sciences companies need to assess their third-party business partners

Defining 'market access'

Compliance issues around sampling will be featured at upcoming conference